Hal Barron

Type: Person

Name: Hal Barron

First reported May 20 2013 - Updated May 21 2013 - 1 reports

Lung cancer gene test approved as 'companion diagnostic'

The US medicines regulator, the Food and Drug Administration (FDA), has approved a genetic test to help doctors select suitable lung cancer patients to be treated with the drug erlotinib (sold as Tarceva).The diagnostic from Roche is the first licensed ... [Published BioNews - May 20 2013]

Entities: erlotinib, Lung Cancer, Companion Diagnostics

First reported May 14 2013 - Updated May 15 2013 - 6 reports

The Latest Treatment for EGFR Mutation in Lung Cancer Patients: Tarceva Tablets

Now people suffering from metastatic non-small cell lung cancer can live longer, without further deterioration of disease with the help of a tablet. Yes, Tarceva tablets have been approved by the U. S. Food and Drug Administration, or FDA, to be used ... [Published TopNews United States - May 15 2013]

Entities: erlotinib, Lung Cancer, Mutation, Patient

First reported May 10 2013 - Updated May 10 2013 - 1 reports

Genentech Inc

Genentech receives FDA approval for juvenile idiopathic arthritis drug

Genentech, a biotechnology company, has received the FDA approval for ACTEMRA for the treatment of polyarticular juvenile idiopathic arthritis, or PJIA. The medicine can be used in children two years of age and older with active disease. ACTEMRA can be ... [Published Individual.com - May 10 2013]

Entities: Genentech Inc, Actemra, Drugs, Hal Barron

First reported Apr 29 2013 - Updated Apr 29 2013 - 1 reports

Astellas Pharma Inc

Two new cancer drugs recommended in Europe

CHMP backing for Roche’s Erivedge and Astellas’ XtandiThe European Medicines Agency (EMA) has recommended EU marketing approval for both Roche's Erivedge and Astellas' Xtandi in oncology indications.In its latest round-up of opinions, the EMA's Committee ... [Published PMLive - Apr 29 2013]

Entities: Xtandi, Erivedge, basal cell carcinoma, Astellas Pharma Inc, European Medicines Agency

First reported Feb 23 2013 - Updated Feb 24 2013 - 1 reports

Roche Holding AG

Roche's T-DM1 Crosses Finish Line as Kadcyla

The second ADC in the past year has crossed the finish line to be approved by the FDA. This time it is Roche's (Genentech) Kadcyla to be used in the treatment of HER2 positive breast cancers. The drug has performed in clinicals -- despite missing out ... [Published The Big Red Biotech Blog - Feb 23 2013]

Entities: Kadcyla, Roche Holding AG, T-DM1, Finish line

First reported Jan 24 2013 - Updated Jan 24 2013 - 1 reports

Avastin Approved For New Use In Colon Cancer Treatment By FDA

Jan 23 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved the use of Roche's Avastin for patients whose colorectal cancer has worsened despite previous treatment with the drug. The new use will allow patients first treated with ... [Published The Huffington Post | Full News Feed - Jan 24 2013]

Entities: Avastin, Colorectal Cancer, Chemotherapy

Quotes

As said by Hal Barron, CMO, Genentech Global Product Development: "10 to 30% of people worldwide with lung cancer have tumors that test positive for certain egfr mutations. people with this type of lung cancer now have the option to use a personalized medicine as their initial treatment to help them live longer without their disease worsening" . However, a few common side effects of this tablet are weakness, cough, diarrhea, rash, shortness of breath and decreased appetite

The Latest Treatment for EGFR Mutation in Lung Cancer Patients: Tarceva Tablets [Published TopNews United States - May 15 2013]

...to make a difference to the lives of people facing this disease," said Hal Barron M D , chief medical officer and head, Global Product Development. "from harnessing a person's immune system to delivering chemotherapy directly to a cancer cell, we believe the new data from our pipeline presented at asco have the potential to markedly change how cancer is treated."

Roche to present important new data reflecting broad cancer pipeline at ASCO [Published Noodls - May 15 2013]

...debilitating condition in children that worsens over time," said Hal Barron, M D , chief medical officer and head, Global Product Development. "we are pleased to offer actemra to doctors and parents of children aged two or older as an important medicine to help improve the signs and symptoms of this often painful disease."

Genentech receives FDA approval for juvenile idiopathic arthritis drug [Published Individual.com - May 10 2013]

More Content

sort by: Date \| Relevance
Lung cancer gene test approved as 'companion di... [Published BioNews - May 20 2013]
Tarceva diagnostic brings new indication [Published Medical Marketing And Media - May 16 2013]
Roche wins new targeted OK for Tarceva in EGFR-... [Published FiercePharma - May 15 2013]
Tarceva and EGFR Mutation Test get US FDA Appr... [Published ITechPost - May 15 2013]
The Latest Treatment for EGFR Mutation in Lung ... [Published TopNews United States - May 15 2013]
Roche Wins U.S. Approval for Test Targeting Lun... [Published La Repubblica - May 15 2013]
Roche to present important new data reflecting ... [Published Noodls - May 15 2013]
ROCHE HOLDING LTD.: Roche to present important ... [Published 4 Traders - May 15 2013]
Roche Wins U.S. Approval for Test Targeting Lun... [Published La Repubblica - May 15 2013]
Genentech to Present Important New Data Reflect... [Published EquityJungle - v0.1 - May 15 2013]
Genentech's Receives U.S FDA Approval For Tarce... [Published RTTNews.com - May 15 2013]
Roche Wins FDA Approval for Test to Target Lung... [Published Bloomberg - May 14 2013]
FDA approves Roche diagnostic for gene mutation... [Published Reuters UK - May 14 2013]
Genentech receives FDA approval for juvenile id... [Published Individual.com - May 10 2013]
CHUGAI PHARMACEUTICAL CO., LTD.: FDA Approves A... [Published 4 Traders - May 07 2013]
Kids Get New Rx for Rare Arthritis [Published Daily Rx - May 02 2013]
FDA Approves Actemra for Children with Polyarti... [Published Drugs.com - May 01 2013]
Roche's (RHHBY) Genentech Receives FDA Approval... [Published Street Insider - Apr 30 2013]
FDA Approves ACTEMRA® for Children Living with ... [Published Business Wire - Apr 30 2013]
EU committee recommends conditional approval of... [Published PharmaBiz - Apr 30 2013]
CHMP recommends conditional EU approval of Roch... [Published European Pharmaceutical Review - Apr 29 2013]
Two new cancer drugs recommended in Europe [Published PMLive - Apr 29 2013]
Rocheâs Pegasys gets European expanded approval... [Published PharmaBiz - Mar 19 2013]
EU approves Roche' Perjeta for patients with pr... [Published PharmaBiz - Mar 06 2013]
Roche's T-DM1 Crosses Finish Line as Kadcyla [Published The Big Red Biotech Blog - Feb 23 2013]
Roche, Chiasma ink pact to develop and commerci... [Published PharmaBiz - Feb 19 2013]
Roche's phase III study of leukaemia drug obinu... [Published PharmaBiz - Feb 01 2013]
Roche gets US FDA nod for new use of Avastin pl... [Published PharmaBiz - Jan 25 2013]
Avastin Approved For New Use In Colon Cancer Tr... [Published The Huffington Post \| Full News Feed - Jan 24 2013]
US FDA extends approval of Roche's Tamiflu for ... [Published PharmaBiz - Dec 26 2012]